VCYT vs PAHC

For growth investors, Phibro Animal Health Corporation (PAHC) is the stronger pick with 27.

4% revenue growth year-over-year, versus 16. 0% for Veracyte, Inc. (VCYT). Phibro Animal Health Corporation (PAHC) offers the better valuation at 36. 3x trailing P/E (14. 2x forward), making it the more compelling value choice. Analysts rate Veracyte, Inc. (VCYT) a "Buy" — based on 20 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Phibro Animal Health Corporation (PAHC) is the cheapest at 36.

3x versus Veracyte, Inc. at 49. 7x. On forward P/E, Phibro Animal Health Corporation is actually cheaper at 14. 2x.

Over the past 5 years, Phibro Animal Health Corporation (PAHC) delivered a total return of +66.

0%, compared to -8. 1% for Veracyte, Inc. (VCYT). Over 10 years, the gap is even starker: VCYT returned +638. 4% versus PAHC's +128. 6%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Phibro Animal Health Corporation (PAHC) is the lower-risk stock at 1.

38β versus Veracyte, Inc. 's 1. 52β — meaning VCYT is approximately 10% more volatile than PAHC relative to the S&P 500. On balance sheet safety, Veracyte, Inc. (VCYT) carries a lower debt/equity ratio of 3% versus 3% for Phibro Animal Health Corporation — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), Phibro Animal Health Corporation (PAHC) is pulling ahead at 27.

4% versus 16. 0% for Veracyte, Inc. (VCYT). On earnings-per-share growth, the picture is similar: Phibro Animal Health Corporation grew EPS 1883% year-over-year, compared to 164. 5% for Veracyte, Inc.. Over a 3-year CAGR, VCYT leads at 20. 4% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Veracyte, Inc.

(VCYT) is the more profitable company, earning 12. 8% net margin versus 3. 7% for Phibro Animal Health Corporation — meaning it keeps 12. 8% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: VCYT leads at 14. 3% versus 8. 5% for PAHC. At the gross margin level — before operating expenses — VCYT leads at 69. 6%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

On forward earnings alone, Phibro Animal Health Corporation (PAHC) trades at 14.

2x forward P/E versus 24. 6x for Veracyte, Inc. — 10. 3x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PAHC: 13. 5% to $49. 00.

In this comparison, PAHC (1.

1% yield) pays a dividend. VCYT does not pay a meaningful dividend and should not be held primarily for income.

For long-horizon retirement investors, Phibro Animal Health Corporation (PAHC) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (1.

1% yield, +128. 6% 10Y return). Veracyte, Inc. (VCYT) carries a higher beta of 1. 52 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (PAHC: +128. 6%, VCYT: +638. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

PAHC pays a dividend while VCYT does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.